Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib for chronic spontaneous urticaria – Phase IIb randomized double-blind placebo-controlled trial
CTR20255053Phase 2Active
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ritlecitinib tosilate in chronic idiopathic urticaria (CIU), sponsored by Pfizer. Started Feb 2026; status: active.
02
Drugs
ritlecitinib tosilate
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20255053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255053.